An observational study in Fungal Allergy and Allergy, sponsored by Medical University of Vienna. Status unknown at 1 site in Austria. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-12.
Sponsored by Medical University of Vienna · Observational
Mold allergies are becoming increasingly important among the population. Increasing amounts of fungal spores are analyzed in air-samples because of urbanization, industrialization of food products and climate change. Mold also grows indoor and hence lead to additional health complaints.
Alternaria alternata, and its only major allergen Alt a 1, is the most important fungus for allergy sufferers. Alternaria alternata can not only cause allergic symptoms but can also cause intensified asthmatic symptoms.
Besides Alternaria alternata, there are over 700 other species of the genus Alternaria. The influence of these other species on allergic symptoms is poorly understood.
Furthermore, prevalence and incidence of an allergy to Alternaria alternata among the Austrian population is not known. Estimates range between 1-5% among the Austrian population.
This study aims to further investigate the incidence and characteristics of an allergy to Alternaria in Austria. This will be investigated with the help of participants (50 Alternaria allergy sufferers and 20 non allergic participants), spore counts in Austria and crowd-sourced symptom data.
1,925 studies on the registry are indexed under Hypersensitivity; 261 are open to participants now.
This study's planned enrollment of 70 is below the median of 113 across 482 observational studies indexed under Hypersensitivity.
Browse Hypersensitivity studies →Medical University of Vienna is the lead sponsor of 1,105 studies on the registry; 182 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Participants are recruited with the help of advertisements on the social media pages of the Austrian Pollen Information Service and on the pollen diary app
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
50 people suffering from an allergy to Alternaria. These participants receive a questionnaire, a Skin-Prick-Test, a blood draw and nasal provocation with collection of nasal secretion
Diagnostic Test: Nasal provocation · Diagnostic Test: Skin-Prick Test · Diagnostic Test: Blood draw · Diagnostic Test: Collection of nasal secretion
Non allergic participants (20) receive a questionnaire, a blood draw and collection of nasal secretion
Diagnostic Test: Blood draw · Diagnostic Test: Collection of nasal secretion
Nasal provocation with Alternaria alternata extract. Changes in nasal mucosa are measured with a rhinomanometry device
Skin-Prick-Test is administered to determine an allergy against Alternaria
For further analysis
Allergy sufferers: After nasal provocation Non-allergics: After administration of isotonic nasal spray
Prevalence, Immunoglobulin-E (IgE)-antibodies to selected Alternaria species
Determine the prevalence of sensitization to multiple Alternaria species in the Austrian population
Time frame: 12 months
Cytokine-profile (e.g. Interleukin-13, Interleukin-5, Interleukin-10, TNFalpha, IFNgamma) upon Alt a 1 incubation
Changes in the immun response when ligand-binding mononuclear cells from the blood to Alt a 1, characterized by the cytokine profile (Th1/Th2/regulatory) and the cell population (B- and T-cells, macrophages/monocytes)
Time frame: 12 months
Started Oct 2021 (actual). Primary completion is estimated for Jul 2023, 21 months after the start.
Of 158 non-industry observational studies under Hypersensitivity, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 109. This study's planned 21 months is below that.
Counting every sponsor, half of 181 studies reached it within 30 months; a quarter within 13 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Vienna →